Source: FDA Enforcement Reports · Last updated October 19, 2026

Which blood pressure medications are recalled in 2026?

As of October 19, 2026, FDA’s 2026 Enforcement Reports list recalls of certain lots of metoprolol succinate ER (Teva, Ascend), amlodipine/olmesartan (Ascend), chlorthalidone (Inventia), clonidine patches (Teva), furosemide, bisoprolol/HCTZ and Diovan (valsartan) 160 mg. All of the FDA-listed ones are Class II, mostly for tablets that failed dissolution specifications or for impurity or manufacturing (CGMP) problems. Only specific lots are affected. Check the NDC and lot number on your pharmacy label or the manufacturer’s bottle. Don’t stop taking your blood pressure medicine on your own. Call your pharmacist, who can tell you whether your fill came from a recalled lot and swap it if needed.

Last updated: October 19, 2026 · Sources: FDA Enforcement Reports via openFDA (data through October 7, 2026); Ascend recall letter

FDA records

16

Medicines

7

Class

All Class II

Latest FDA data

October 7, 2026

Scope: recalls of blood pressure medicines we found in FDA’s 2026 Enforcement Reports as of October 19, 2026. This is not guaranteed to be a complete list. Blood pressure monitor (device) recalls are not included.

Recalled blood pressure medicines at a glance

• Metoprolol succinate ER: D-0354-2026, D-0355-2026, D-0356-2026, D-0357-2026, D-0547-2026
• Amlodipine/olmesartan: D-0556-2026, D-0712-2026 + 10 mg/40 mg lot per Ascend letter (FDA record pending)
• Chlorthalidone: D-0610-2026, D-0852-2026
• Clonidine transdermal: D-0472-2026, D-0473-2026, D-0474-2026
• Furosemide: D-0293-2026, D-0486-2026
• Bisoprolol/HCTZ; Diovan 160 mg: D-0301-2026, D-0746-2026

Metoprolol succinate ER recall (Teva, Ascend)

Teva recalled certain lots of 25, 50, 100 and 200 mg metoprolol succinate extended-release tablets, and Ascend recalled one 25 mg lot, all for “Failed Dissolution Specifications” (Class II). Lot numbers are shown exactly as FDA printed them (for example, “10688H251” in D-0357-2026).

Amlodipine and olmesartan (Ascend)

Also recalled, per Ascend’s recall letter (October 6, 2026; FDA record pending): Amlodipine and Olmesartan Medoxomil Tablets 10 mg/40 mg, 30 tablets per bottle, NDC 67877-502-30, lot 25120696, expiration December 31, 2026, quantity distributed 11,424 bottles. Ascend says “an out-of-specification (OOS) result was identified for the dissolution assay of the Olmesartan Medoxomil component. The dissolution results for Amlodipine were within the established acceptance criteria.” The letter says the recall is being carried out to the RETAIL level. We have not seen FDA’s enforcement record for this lot yet, so no FDA recall number or class is shown. Ascend product inquiries: 877-272-7901.

Chlorthalidone (Inventia)

Clonidine patches (Teva)

Furosemide

Bisoprolol/HCTZ and Diovan (valsartan)

Telmisartan / amlodipine: reported, not yet in FDA data

Third-party recall trackers have reported a telmisartan/amlodipine recall. As of October 19, 2026 we could not find it in FDA’s published enforcement data or in an official company notice, so we don’t list details here. We’ll add it if FDA publishes it.

How to find the NDC and lot number on your pill bottle

• Manufacturer’s bottle or carton: the NDC is printed on the label, and the lot number is usually next to the expiration date.
• Pharmacy-filled bottle: the label may show the NDC or the manufacturer but often not the lot. Ask your pharmacist which manufacturer and lot they dispensed.

More: where to find a lot number · search all FDA drug recalls

Should I stop taking it?

No. Don’t stop taking your blood pressure medicine without talking to your pharmacist or doctor. Ask your pharmacist whether your fill came from a recalled lot; Ascend’s letter, for example, says its recall is being carried out to the RETAIL level.

What “failed dissolution” and “Class II” mean

Failed dissolution: in testing, the tablet didn’t release its drug the way its specification requires. Ascend says delayed dissolution “may delay the onset of the drug’s pharmacological action.”

Class II (FDA): a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. See FDA Enforcement Reports.

Official sources

• FDA Enforcement Reports — Checked: October 19, 2026
• openFDA drug enforcement reports (16 records; data through October 7, 2026) — Checked: October 19, 2026
• Ascend Laboratories recall letter: amlodipine/olmesartan 10 mg/40 mg (Oct. 6, 2026, PDF) — Checked: October 19, 2026

This page is not medical advice. Not affiliated with FDA or any drug maker.

FAQ